MediWound Ltd.
MDWDAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 16, 2026 | Industrial Alliance Securities | $27.00(+101%) | $13.44 | TheFly | |
| Aug 14, 2026 | Oppenheimer | Jeff Jones | $30.00(+121%) | $13.58 | TheFly |
| May 28, 2026 | Industrial Alliance Securities | $22.00(+51%) | $14.56 | TheFly | |
| May 27, 2026 | Oppenheimer | Jay Olson | $32.00(+123%) | $14.33 | StreetInsider |
| Nov 21, 2025 | H.C. Wainwright | $36.00(+114%) | $16.86 | TheFly | |
| May 22, 2025 | H.C. Wainwright | Swayampakula Ramakanth | $31.00(+52%) | $20.34 | TheFly |
| Feb 28, 2025 | Craig-Hallum | $39.00(+135%) | $16.60 | TheFly | |
| Oct 11, 2024 | H.C. Wainwright | Swayampakula Ramakanth | $28.00(+65%) | $16.92 | StreetInsider |
| May 29, 2024 | Oppenheimer | Francois Brisebois | $36.00(+125%) | $16.01 | StreetInsider |
| Jan 4, 2023 | H.C. Wainwright | $23.00(+73%) | $13.29 | Benzinga | |
| Dec 30, 2022 | Cowen & Co. | $25.00(+85%) | $13.49 | Benzinga | |
| Dec 22, 2022 | Maxim Group | $25.00(+127%) | $11.01 | Benzinga | |
| Nov 16, 2022 | H.C. Wainwright | $5.50(+2205%) | $0.24 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Oppenheimer | maintain | Outperform | Aug 14, 2026 |
| Oppenheimer | maintain | Outperform | May 28, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 28, 2026 |
| HC Wainwright & Co. | maintain | Buy | Nov 21, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 22, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 20, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 10, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 27, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 11, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 16, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 30, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 22, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jan 16, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 22, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 21, 2023 |
| Oppenheimer | maintain | Outperform | Aug 17, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 17, 2023 |
| Oppenheimer | maintain | Outperform | May 31, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 31, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 17, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jan 4, 2023 |
| Cowen & Co. | maintain | Outperform | Dec 30, 2022 |
| Maxim Group | maintain | Buy | Dec 22, 2022 |
| Oppenheimer | maintain | Outperform | Dec 21, 2022 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.71| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.77 | $-0.76 | $3.1M | $2.6M |
| May 27, 2026 | $-0.23 | $-0.65 | $1.5M | $3.4M |
| Mar 5, 2026 | $-0.56 | $-0.65 | $1.9M | $4.2M |
| Nov 20, 2025 | $-0.24 | $-0.81 | $5.4M | $2.1M |
| Aug 14, 2025 | $-1.23 | $-0.55 | $5.7M | $6.6M |
| May 21, 2025 | $-0.07 | $-0.65 | $4.0M | $5.8M |
| Mar 19, 2025 | $-0.36 | $-0.59 | $5.8M | $5.3M |
| Nov 26, 2024 | $-0.98 | $-0.44 | $4.4M | $5.8M |
News
MediWound Announces Closing of $17. 25 Million Bought Deal Offering of Ordinary Shares YAVNE, Israel, November 5, 2026 (GLOBE NEWSWIRE) - MediWound Ltd. (Nasdaq: MDWD) ("MediWound"), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the closing of its previously announced underwritten public offering of 1,380,000 ordinary shares, including 180,000 ordinary shares issued pursuant to the full exercise of the underwriter's option to purchase additional ord…
MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares YAVNE, Israel, November 3, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it has entered into an underwriting agreement with H.C.
MediWound to Report Third Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Thursday, November 12 th at 8:30 a.m. Eastern Time YAVNE, Israel, October 29, 2026 -- MediWound Ltd.
Taysha Gene Therapies (NASDAQ: TSHA - Get Free Report) and MediWound (NASDAQ: MDWD - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation. Earnings and Valuation This table compares Taysha
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid ®
Independent DSMB Recommends MediWound's EscharEx ® Phase III VALUE Study Continue Without Modification DSMB did not identify safety concerns in pre-specified review; interim assessment and enrollment completion remain on track for end of the first quarter of 2027 YAVNE, Israel, September 14, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the independent Data and Safety Monitoring Board (DSMB…
MediWound to Present at the H.C. Wainwright 28 th Annual Global Investment Conference YAVNE, Israel, September 2, 2026 -- MediWound Ltd.
MediWound Ltd. (MDWD) Q2 2026 Earnings Call Transcript
MediWound NASDAQ: MDWD reported second-quarter 2026 revenue of $3.1 million, down from $5.7 million a year earlier, as the company continued investing in its Phase III EscharEx chronic-wound program and expanded development work around its NexoBrid burn treatment.
MediWound (MDWD) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to a loss of $1.23 per share a year ago.
EscharEx ® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under its BARDA Contract for NexoBrid ® Second Quarter Revenue of $3.1 Million; Full-Year 2026 Revenue Guidance of $24–26 Million Reaffirmed Conference Call Today at 8:30 a.m. Eastern Time YAVNE, Israel, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MediWound Ltd.